Praveen Chandra1, Tarun Kumar2. 1. Department of Intervention Cardiology, Medanta the Medicity, Gurgaon, India. Electronic address: praveen.chandra@medanta.org. 2. Department of Intervention Cardiology, Medanta the Medicity, Gurgaon, India.
Abstract
AIM: A prospective, multicenter, post marketing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India. PRIMARY OBJECTIVE: 1. To study the MACE and in stent and In-segment Loss at Six Months (in a pre selected group of 50 patients). SECONDARY OBJECTIVE: 1. Clinical and procedural success. MATERIALS AND METHODS: This is a prospective, open label, single-arm, multicenter (16 sites), post marketing observational study enrolling patients implanted with Superia-Sirolimus Eluting Coronary Stent (SSECS) in routine clinical practice in India. A total of 200 Patients of coronary Artery Disease (CAD) implanted with Superia-Sirolimus Eluting Coronary Stent (SSECS) were enrolled. Clinical assessments were done at 30 days, 180 days and at 1, 2 years either telephonically or office visit. A cohort of 50 pre-selected patients were followed up for angiographic evaluation at 180 days. RESULTS: MACE at 12 month of follow up was 1.71%.Late lumen loss, in segment was 0.14 and in stent was 0.10 mm at 6 month of follow-up. TLR was required only in 2 patients. CONCLUSION: Superia stent is as safe as other biodegradable polymer stent in the market and time has come for biodegradable polymer stent with thin struts.
AIM: A prospective, multicenter, post marketing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India. PRIMARY OBJECTIVE: 1. To study the MACE and in stent and In-segment Loss at Six Months (in a pre selected group of 50 patients). SECONDARY OBJECTIVE: 1. Clinical and procedural success. MATERIALS AND METHODS: This is a prospective, open label, single-arm, multicenter (16 sites), post marketing observational study enrolling patients implanted with Superia-Sirolimus Eluting Coronary Stent (SSECS) in routine clinical practice in India. A total of 200 Patients of coronary Artery Disease (CAD) implanted with Superia-Sirolimus Eluting Coronary Stent (SSECS) were enrolled. Clinical assessments were done at 30 days, 180 days and at 1, 2 years either telephonically or office visit. A cohort of 50 pre-selected patients were followed up for angiographic evaluation at 180 days. RESULTS: MACE at 12 month of follow up was 1.71%.Late lumen loss, in segment was 0.14 and in stent was 0.10 mm at 6 month of follow-up. TLR was required only in 2 patients. CONCLUSION: Superia stent is as safe as other biodegradable polymer stent in the market and time has come for biodegradable polymer stent with thin struts.
Authors: Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico Journal: N Engl J Med Date: 2002-06-06 Impact factor: 91.245
Authors: Ian T Meredith; Stephen Worthley; Robert Whitbourn; Darren L Walters; Dougal McClean; Mark Horrigan; Jeffrey J Popma; Donald E Cutlip; Ann DePaoli; Manuela Negoita; Peter J Fitzgerald Journal: JACC Cardiovasc Interv Date: 2009-10 Impact factor: 11.195
Authors: Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245
Authors: Bimmer E Claessen; Marcel A Beijk; Victor Legrand; Witold Ruzyllo; Antonio Manari; Olivier Varenne; Maarten J Suttorp; Jan G P Tijssen; Karine Miquel-Hebert; Susan Veldhof; Jose P S Henriques; Patrick W Serruys; Jan J Piek Journal: Circ Cardiovasc Interv Date: 2009-07-22 Impact factor: 6.546
Authors: Sripal Bangalore; Bora Toklu; Nicholas Amoroso; Mario Fusaro; Sunil Kumar; Edward L Hannan; David P Faxon; Frederick Feit Journal: BMJ Date: 2013-11-08